Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 8:10:11-20.
doi: 10.2147/LCTT.S179349. eCollection 2019.

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Stephanie M Barrows  1 , Kelly Wright  1 , Catherine Copley-Merriman  1 , James A Kaye  2 , Marc Chioda  3 , Robin Wiltshire  4 , Knut Martin Torgersen  5 , Elizabeth T Masters  6
Affiliations
Review

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Stephanie M Barrows et al. Lung Cancer (Auckl). .

Abstract

The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4-89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5-22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors.

Keywords: ALK; NSCLC; carcinoma; non-small-cell lung; non-small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure Elizabeth T Masters, Marc Chioda, Robin Wiltshire, and Knut Martin Torgersen are employees of Pfizer, Inc. RTI Health Solutions received funding from Pfizer to conduct this research and for manuscript development; Stephanie M Barrows, Kelly Wright, Catherine Copley-Merriman, and James A Kaye are employees of RTI Health Solutions. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
PRISMA diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene. 1997;14(18):2175–2188. - PubMed
    1. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22(4):508–515. - PubMed
    1. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723–1733. - PubMed
    1. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010;18(6):548–551. - PMC - PubMed
    1. Lee JK, Park HS, Kim DW, et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer. 2012;118(14):3579–3586. - PubMed